Glaukos (NYSE:GKOS) yesterday reported widening losses during its 2nd quarter, but shares held on for the glaucoma-treatment focused company. Laguna Hills, Calif.-based Glaukos reported losses of $32.5 million, or $10.96 per share, on sales of $17.8 million for the 3 months ended June 30. That amounts to a whopping 1000% plus increase in losses on sales […]
Glaukos
Glaukos iStent wins nod from Health Canada
Glaukos (NYSE:GKOS) said today it won approval from Health Canada for its iStent Inject trabecular micro-bypass stent designed for use in cataract surgeries to treat glaucoma. The newly cleared iStent inject is indicated for micro-invasive glaucoma surgery procedures to reduce intraocular pressure in patients with primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma, the Laguna Hills, […]
Glaukos wins iStent nod Down Under
Glaukos (NYSE:GKOS) said today it won approval from the Australian Therapeutic Goods Administration for its iStent Inject trabecular micro-bypass stent designed for use in cataract surgeries to treat glaucoma. The device is indicated for the reduction of intraocular pressure in adult patients with mild-to-moderate glaucoma who are currently being treated with ocular hypotensive medication, the Laguna […]
Glaukos closes $140m IPO, puts up $26m for Dose Medical affiliate
Glaukos (NYSE:GKOS) yesterday said it closed its $140 million initial public offering with it underwriters exercising their over-allotment option, meaning net proceeds for the glaucoma device maker of roughly $112.3 million. Laguna Hills, Calif.-based Glaukos said J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co. acted as joint book-running managers, with William Blair and Cantor Fitzgerald […]
Glaukos raises the stakes in $99m IPO
Glaukos today raised the proposed price range on its pending initial public offering, saying it will offer 6 million shares at $16 to $17 apiece, which at the midpoint would fetch $99.0 million. In May, Laguna Hills, Calif.-based Glaukos initially said the offering could gross as much as $86.2 million. Earlier this month the company said it planned […]
Glaukos looks to $86m IPO
Glaukos yesterday registered for an initial public offering worth as much as $86.2 million.
The iStent made by Laguna Hills, Calif.-based Glaukos was the 1st micro-invasive glaucoma surgery device to hit the U.S. market. It’s a tiny titanium stent designed to alleviate the intra-ocular pressure caused by glaucoma.
Medical Device Venture Capital Report for January 2013
Medical device companies pulled in more than $255 million from investors in 29 deals during January, according to data provided to MassDevice.com by CB Insights Inc.
The deals ranged widely in size, from a $25,000 seed round investment for Elyira, Ohio-based Guided Interventions and its passive coronary artery blockage sensing technology to a $43 million Series D round for EndoChoice and its endoscopes.
FDA OKs Glaukos’ iStent for cataract surgery
The FDA said it gave pre-market approval to Glaukos Corp. to market its iStent device in the U.S. for cataract surgeries.